335 related articles for article (PubMed ID: 9150188)
1. Expression of p53, glutathione S-transferase-pi, and Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer.
Silvestrini R; Veneroni S; Benini E; Daidone MG; Luisi A; Leutner M; Maucione A; Kenda R; Zucali R; Veronesi U
J Natl Cancer Inst; 1997 May; 89(9):639-45. PubMed ID: 9150188
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
3. The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol.
Silvestrini R; Daidone MG; Veneroni S; Benini E; Scarfone G; Zanaboni F; Villa A; Presti M; Danese S; Bolis G
Cancer; 1998 Jan; 82(1):159-67. PubMed ID: 9428493
[TBL] [Abstract][Full Text] [Related]
4. p53 as an independent prognostic marker in lymph node-negative breast cancer patients.
Silvestrini R; Benini E; Daidone MG; Veneroni S; Boracchi P; Cappelletti V; Di Fronzo G; Veronesi U
J Natl Cancer Inst; 1993 Jun; 85(12):965-70. PubMed ID: 8496982
[TBL] [Abstract][Full Text] [Related]
5. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients.
Silvestrini R; Veneroni S; Daidone MG; Benini E; Boracchi P; Mezzetti M; Di Fronzo G; Rilke F; Veronesi U
J Natl Cancer Inst; 1994 Apr; 86(7):499-504. PubMed ID: 8133533
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of glutathione S-transferase-pi in invasive breast cancer.
Huang J; Tan PH; Thiyagarajan J; Bay BH
Mod Pathol; 2003 Jun; 16(6):558-65. PubMed ID: 12808061
[TBL] [Abstract][Full Text] [Related]
7. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.
von Minckwitz G; Sinn HP; Raab G; Loibl S; Blohmer JU; Eidtmann H; Hilfrich J; Merkle E; Jackisch C; Costa SD; Caputo A; Kaufmann M;
Breast Cancer Res; 2008; 10(2):R30. PubMed ID: 18380893
[TBL] [Abstract][Full Text] [Related]
8. Biological markers as indicators of pathological response to primary chemotherapy in oral-cavity cancers.
Costa A; Licitra L; Veneroni S; Daidone MG; Grandi C; Cavina R; Molinari R; Silvestrini R
Int J Cancer; 1998 Dec; 79(6):619-23. PubMed ID: 9842971
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of pi-class glutathione S-transferase expression in breast cancer: correlation with estrogen receptor expression and prognosis in node-negative breast cancer.
Gilbert L; Elwood LJ; Merino M; Masood S; Barnes R; Steinberg SM; Lazarous DF; Pierce L; d'Angelo T; Moscow JA
J Clin Oncol; 1993 Jan; 11(1):49-58. PubMed ID: 8418241
[TBL] [Abstract][Full Text] [Related]
10. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].
Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J
Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497
[TBL] [Abstract][Full Text] [Related]
11. Prognostic indicators for breast cancer patients with one to three regional lymph node metastases, with special reference to alterations in expression levels of bcl-2, p53 and c-erbB-2 proteins.
Zhang GJ; Tsuda H; Adachi I; Fukutomi T; Yamamoto H; Hirohashi S
Jpn J Clin Oncol; 1997 Dec; 27(6):371-7. PubMed ID: 9437997
[TBL] [Abstract][Full Text] [Related]
12. p53 and c-erbB-2 but not bcl-2 are predictive of metastasis-free survival in breast cancer patients receiving post-mastectomy adjuvant radiotherapy in Taiwan.
Chen HH; Su WC; Guo HR; Chang TW; Lee WY
Jpn J Clin Oncol; 2002 Sep; 32(9):332-9. PubMed ID: 12417598
[TBL] [Abstract][Full Text] [Related]
13. p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients.
Silvestrini R; Benini E; Veneroni S; Daidone MG; Tomasic G; Squicciarini P; Salvadori B
J Clin Oncol; 1996 May; 14(5):1604-10. PubMed ID: 8622078
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical biomarkers in patients with early-onset breast carcinoma by tissue microarray.
Choi DH; Kim S; Rimm DL; Carter D; Haffty BG
Cancer J; 2005; 11(5):404-11. PubMed ID: 16259871
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of p53 and bcl-2 expression in patients treated with breast conservative therapy.
Kim K; Chie EK; Han W; Noh DY; Park IA; Oh DY; Im SA; Kim TY; Bang YJ; Ha SW
J Korean Med Sci; 2010 Feb; 25(2):235-9. PubMed ID: 20119576
[TBL] [Abstract][Full Text] [Related]
16. Time for integration of predictive factors for selection of breast cancer patients who need postoperative radiation therapy?
Bergh J
J Natl Cancer Inst; 1997 May; 89(9):605-7. PubMed ID: 9150179
[No Abstract] [Full Text] [Related]
17. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum.
Boku N; Chin K; Hosokawa K; Ohtsu A; Tajiri H; Yoshida S; Yamao T; Kondo H; Shirao K; Shimada Y; Saito D; Hasebe T; Mukai K; Seki S; Saito H; Johnston PG
Clin Cancer Res; 1998 Jun; 4(6):1469-74. PubMed ID: 9626464
[TBL] [Abstract][Full Text] [Related]
18. [Evidence-based radiotherapy in the treatment of early-stage invasive breast cancer: traditional clinical features and biomarkers].
Fodor J
Magy Onkol; 2009 Mar; 53(1):7-14. PubMed ID: 19318321
[TBL] [Abstract][Full Text] [Related]
19. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
[TBL] [Abstract][Full Text] [Related]
20. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
